HHCP
BDRX

Hilton Head Capital Partners’s Biodexa Pharmaceuticals BDRX Stock Holding History

Hilton Head Capital Partners’s Portfolio BDRX Stock Details BDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17 Hold
6
– – ﹤0.01% 908
2026
Q1 		$19 Hold
6
– – ﹤0.01% 983
2025
Q4 		$68 Buy
+6
New +$171 ﹤0.01% 919

Other funds holding BDRX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
APW
Allied Private Wealth Boca Raton, Florida $156M AUM
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Hilton Head Capital Partners's BDRX Position: Q2 2026 in Review

Hilton Head Capital Partners held its Biodexa Pharmaceuticals (BDRX) position steady in Q2 2026 at 6 shares worth $17. The position accounts for ﹤0.01% of the portfolio, ranked #908.

Hilton Head Capital Partners first reported a position in BDRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $68 in Q4 2025. 8 funds tracked by Wall St. Rank hold BDRX as of Q2 2026.

  • Hilton Head Capital Partners held 6 shares of Biodexa Pharmaceuticals worth $17 as of Q2 2026.
  • Hilton Head Capital Partners left its Biodexa Pharmaceuticals share count unchanged in Q2 2026.
  • Biodexa Pharmaceuticals made up ﹤0.01% of Hilton Head Capital Partners's portfolio in Q2 2026, its #908 holding.
  • Hilton Head Capital Partners first reported a position in Biodexa Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Hilton Head Capital Partners's Biodexa Pharmaceuticals position peaked at $68 in Q4 2025.
  • 8 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q2 2026.

Based on Hilton Head Capital Partners's 13F filing for Q2 2026, filed 27 Jul 2026.